TOFACITINIB (Xeljanz) prior authorization at Centene
Submission criteria, P2P prep, and appeal path if denied — for prescribers and PA staff
Centene requires prior-authorization documentation for TOFACITINIB (Xeljanz): a diagnosis with ICD-10 code, documented step-therapy history, and prescriber attestation of medical necessity. Standard PA decisions return in 30 days; if denied, prescribers and members have 60 days to appeal.
The PA criteria you'll need to meet
Centene reviews TOFACITINIB (Xeljanz) prior authorizations against its medical policy . Centene-specific context: Largest Medicaid MCO in US. Markets under Ambetter (ACA), Wellcare (MA), and state-specific Medicaid brands. State-specific appeal processes vary; check state Medicaid handbook.
Documentation packet checklist
- Chart note with diagnosis (ICD-10 code) and clinical severity markers
- Documented failure of, contraindication to, or intolerance of step-therapy alternatives in this class
- Prior treatment history including dosing, duration, and reason for discontinuation
- Relevant labs, imaging, or assessment scores supporting medical necessity
- Prescriber attestation linking the FDA-approved indication to the patient's presentation
- Centene's medical policy URL referenced in the cover letter
Centene's common denial patterns
Pre-empting these patterns in the initial submission cuts rework and shortens time-to-approval:
- Marketplace network adequacy issues
- Medicaid step therapy
- Specialty drug exclusions
TOFACITINIB (Xeljanz)-specific denial patterns and context
Across payers (not just Centene), TOFACITINIB (Xeljanz)draws a distinct set of denial reasons rooted in the drug's label, REMS, and competitive landscape:
- Boxed warning step therapy — TNF-inhibitor required first (FDA 2021 ORAL Surveillance trial)
- Age restriction (≥50 with CV risk factors excluded)
- Indication restriction (RA vs PsA vs UC vs JIA)
Brand: Xeljanz. JAK1/3 inhibitor. FDA boxed warning (September 2021) for increased risk of MACE, malignancy, thrombosis, mortality vs TNF inhibitors — based on ORAL Surveillance trial. Plans now uniformly require TNF-inhibitor failure first.
Manufacturer patient-assistance program: Pfizer XELSOURCE — relevant when a Centene denial sticks and the patient needs bridge access while appealing.
If the PA is denied
Centene gives prescribers and members 60 days to file an internal appeal. Standard appeal decisions return within 30 days. Submit through the provider portal (https://ambetterhealth.com/provider-resources) with the same packet plus a peer-reviewed citation supporting TOFACITINIB (Xeljanz)for the patient's indication.
Medicare Advantage path: if Centene misses the appeal deadline the case auto-forwards to the Independent Review Entity (Maximus). Time-to-decision favors clinicians who request expedited review with a 72-hour clock when the delay risks harm.
Centene as a Medicare Advantage organization operates under 42 CFR Part 422 Subpart D for organization determinations: a standard (non-urgent) pre-service decision is due within 7 calendar days under CMS-0057-F (effective January 1, 2026; reduced from the prior 14-day standard), an expedited decision within 72 hours, and Part B drug decisions within 72 hours under the 2023 step-therapy rule extension. Missed deadlines auto-forward to the Independent Review Entity (Maximus Federal Services) without member action — track the calendar carefully because this is the most reliable lever in MA appeals.
Helping a patient appeal the denial directly? See the consumer guide: How to appeal a Centene denial on DenialHelp.
Contact Centene
- Provider portal: https://ambetterhealth.com/provider-resources
Frequently asked questions
What documentation does Centene need for TOFACITINIB (Xeljanz) prior auth?
Centene's typical PA packet for TOFACITINIB (Xeljanz): (1) chart note documenting the indication and prior-treatment failures, (2) supporting lab/imaging where indicated, (3) prescriber attestation that step-therapy alternatives were tried or contraindicated, (4) FDA-approved indication mapped to ICD-10 diagnosis.
What's the turnaround time at Centene?
Standard TOFACITINIB (Xeljanz) PA decisions at Centene: 30 days. Urgent / expedited (member's life or function at risk): 72 hours under 45 CFR §147.136. Medicare Advantage adds the 14-day extension rule under 42 CFR Part 422.
What does Centene most often reject TOFACITINIB (Xeljanz) for?
Across Centene's book the common rejection patterns include: Marketplace network adequacy issues; Medicaid step therapy; Specialty drug exclusions. For TOFACITINIB (Xeljanz) specifically, expect step-therapy challenges and indication-restriction reviews when the use is at the edge of the FDA label or off-label.
How do I prep for a peer-to-peer with Centene on TOFACITINIB (Xeljanz)?
Lead with the FDA-approved indication and the specific clinical criteria the policy lists. Have the patient's chart open, document number, and policy URL on screen. State your name and credentials, the policy number, the indication, and the documented failures of step-therapy alternatives. Keep notes — if the P2P reviewer overturns, get the decision in writing.
Related PA criteria
Generate the TOFACITINIB (Xeljanz) PA packet
Open ApprovalHelp — generate a TOFACITINIB (Xeljanz) prior-auth packet tailored to Centene's criteria, with prescriber attestation and step-therapy documentation pre-filled.
Get started →Contact: hello@approvalhelp.com